A pooled secondary analysis of the STEP-HFpEF and STEP-HFpEF DM trials examined whether baseline atrial fibrillation modified the benefit of once-weekly semaglutide 2.4 mg in obesity-related HFpEF. PICO summary and expert commentary.
Browsing: Obesity & Weight Management
Pooled patient-reported outcomes from the STEP 1-4 trials show semaglutide 2.4 mg improved physical functioning versus placebo over 68 weeks. PICO summary and expert commentary.
A prespecified analysis of the SELECT randomised trial showing sustained four-year weight loss with semaglutide versus placebo in adults with cardiovascular disease and obesity but no diabetes. PICO summary and expert commentary.
Secondary analysis of the SELECT trial finds once-weekly semaglutide 2.4 mg modestly lowered a composite kidney endpoint versus placebo in adults with overweight or obesity and cardiovascular disease but no diabetes. PICO summary and expert commentary.
Prespecified pooled analysis of the STEP-HFpEF program: once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.
Clinical Context Obesity affects over 650 million adults worldwide and is associated with numerous comorbidities including type 2 diabetes, cardiovascular…
Clinical Context The relationship between obesity and cardiovascular disease has long been recognized, but proving that weight loss reduces cardiovascular…
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) with NYHA class II-IV symptoms, semaglutide 2.4 mg subcutaneous…
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) from pooled STEP-HFpEF trials, stratified by baseline NT-proBNP tertiles,…
Summary: In 1,145 adults with obesity-related HFpEF (BMI ≥30, LVEF ≥45%, NYHA II-IV) pooled from STEP-HFpEF and STEP-HFpEF DM trials,…